Today: The Capital Fund Management S.A. Acquires New Position in Emergent Biosolutions Inc. (EBS)

The Capital Fund Management S.A. Acquires New Position in Emergent Biosolutions Inc. (EBS)

Capital Fund Management S.A. purchased a new stake in shares of Emergent Biosolutions Inc. (NYSE:EBS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 15,600 shares of the biopharmaceutical company’s stock, valued at approximately $439,000.

Other hedge funds have also bought and sold shares of the company. State Street Corp raised its stake in Emergent Biosolutions by 23.3% in the first quarter. State Street Corp now owns 1,099,602 shares of the biopharmaceutical company’s stock valued at $39,969,000 after buying an additional 208,084 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Emergent Biosolutions by 16.9% in the first quarter. Renaissance Technologies LLC now owns 1,112,811 shares of the biopharmaceutical company’s stock valued at $40,451,000 after buying an additional 161,200 shares during the period. Aperio Group LLC increased its position in shares of Emergent Biosolutions by 25.7% in the first quarter. Aperio Group LLC now owns 10,542 shares of the biopharmaceutical company’s stock valued at $383,000 after buying an additional 2,154 shares during the period. Fisher Asset Management LLC increased its position in shares of Emergent Biosolutions by 2.2% in the second quarter. Fisher Asset Management LLC now owns 467,770 shares of the biopharmaceutical company’s stock valued at $14,253,000 after buying an additional 10,028 shares during the period. Finally, HBK Investments L P purchased a new position in shares of Emergent Biosolutions during the first quarter valued at approximately $947,000. Institutional investors and hedge funds own 89.93% of the company’s stock.

Emergent Biosolutions Inc. (NYSE:EBS) traded down 2.61% during trading on Thursday, reaching $30.19. 462,764 shares of the company were exchanged. The stock has a market capitalization of $1.22 billion, a P/E ratio of 21.60 and a beta of 1.12. The company’s 50-day moving average price is $28.61 and its 200-day moving average price is $34.02. Emergent Biosolutions Inc. has a 1-year low of $26.12 and a 1-year high of $44.38.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.01. Emergent Biosolutions had a return on equity of 11.93% and a net margin of 11.61%. The business earned $101.49 million during the quarter, compared to analysts’ expectations of $111.20 million. During the same period in the previous year, the business earned $0.36 earnings per share. The business’s quarterly revenue was down 19.5% on a year-over-year basis. On average, equities analysts forecast that Emergent Biosolutions Inc. will post $1.03 EPS for the current year.

Several equities analysts have recently commented on the stock. Cowen and Company downgraded shares of Emergent Biosolutions from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 22nd. Zacks Investment Research downgraded shares of Emergent Biosolutions from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 5th. Wells Fargo & Co. set a $41.00 price objective on shares of Emergent Biosolutions and gave the company a “buy” rating in a research note on Saturday, October 1st. JPMorgan Chase & Co. lowered their price objective on shares of Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating for the company in a research note on Friday, August 5th. Finally, Singular Research lowered their price objective on shares of Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating for the company in a research note on Tuesday, June 28th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $40.17.

About Emergent Biosolutions

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

Related posts

Leave a Comment